January 12, 2016

Helix BioPharma Corp Announces Appointment of Permanent New CEO and Changes at Board Level (PDF)

(Aurora, Ontario) – Helix BioPharma Corp. (hereinafter defined as “Helix” or the “Company” and listed on TSX & FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, announces that it has appointed Dr. Zbigniew Markowski as Chief Executive Officer, replacing Mr. Gary Littlejohn who was serving as Interim CEO.